Covered recipient · General Payments record
AMY M REESE
Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology
General Payments · PY2018–2024
$8,607.00
- Reported across 356 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,810.06 | 78 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Incyte Corporation | $183.22 | 4 |
| GENZYME CORPORATION | $158.79 | 3 |
| PFIZER INC. | $126.82 | 7 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $122.58 | 6 |
| Merck Sharp & Dohme Corporation | $110.52 | 6 |
| Astellas Pharma US Inc | $109.13 | 5 |
| Lilly USA, LLC | $103.52 | 5 |
| Genmab U.S., Inc. | $75.30 | 4 |
| ABBVIE INC. | $73.53 | 3 |
| Acerta Pharma LLC | $72.30 | 4 |
| Celgene Corporation | $71.79 | 4 |
| Coherus Biosciences Inc. | $69.34 | 2 |
| Sirtex Medical Inc | $63.71 | 1 |
| E.R. Squibb & Sons, L.L.C. | $62.64 | 3 |
| Takeda Pharmaceuticals U.S.A., Inc. | $56.65 | 3 |
| Janssen Biotech, Inc. | $41.23 | 2 |
| Blueprint Medicines Corporation | $35.58 | 2 |
| Bayer HealthCare Pharmaceuticals Inc. | $32.05 | 2 |
| Stemline Therapeutics Inc. | $24.52 | 1 |
| ADC Therapeutics America, Inc. | $24.29 | 1 |
| TAIHO ONCOLOGY, INC. | $24.03 | 1 |
| AVEO Pharmaceuticals, Inc. | $23.40 | 1 |
| GlaxoSmithKline, LLC. | $23.06 | 1 |
| Genentech USA, Inc. | $21.13 | 1 |
| EISAI INC. | $18.84 | 1 |
| Gilead Sciences, Inc. | $18.40 | 1 |
| ARRAY BIOPHARMA INC | $17.23 | 1 |
| Daiichi Sankyo Inc. | $16.44 | 1 |
| Rigel Pharmaceuticals, Inc. | $15.50 | 1 |
| Novocure Inc. | $14.52 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (78)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.